Trial Profile
Retrospective multicenter study of Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Dec 2018
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 07 Dec 2018 New trial record